Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Merger agrmnt [a]
Appointed director
|
|
VYNE Therapeutics Inc. (MNLO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 03/09/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule BRIDGEWATER, N.J., February 28, 2023 -- VYNE Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on February 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550 of the Nasdaq Listing Rules. According to the Notification Letter on Compliance, the staff of Nasdaq has determined that for the last 10 consecutive business days, from February 13, 2023 through February 27, 2023, the closing bid p..." |
|
| 02/10/2023 |
8-K
| Quarterly results |
| 01/17/2023 |
8-K
| Quarterly results |
| 01/12/2023 |
8-K
| Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure,... |
| 11/10/2022 |
8-K
| Quarterly results |
| 08/30/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ... |
| 08/12/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 07/27/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/17/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/07/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/30/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/17/2022 |
8-K
| Quarterly results |
| 03/15/2022 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"VYNE Therapeutics Inc. 520 U.S Highway 22, Suite 204 Bridgewater, New Jersey 08807",
"WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Thirty Million Dollars of the Company’ s common stock, $0.0001 par value per share . The shares of Common Stock to be purchased hereunder are referred to herein as the “ Purchase Shares .” NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows: 1. CERTAIN DEFINITIONS. For purposes of this Agreement, the following terms shall have the following meanings: “ Accelerated Purchase Date ” means, with respect to any Accelerated Purchase made...",
"REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT , dated as of March 15, 2022, is entered into by and between VYNE THERAPEUTICS, INC., a Delaware corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof . WHEREAS: A. Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investor, and the Investor has agreed to purchase, up to Thirty Million Dollars of the Company’ s common stock, par value $0.0001 per share , pursuant to the Purchase Agreement , and the Company has agreed to issue to the Inve..." |
|
| 03/08/2022 |
8-K
| Quarterly results |
| 03/07/2022 |
8-K
| Quarterly results |
| 03/04/2022 |
8-K
| Quarterly results |
| 01/19/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State... |
| 01/05/2022 |
8-K
| Investor presentation |
| 11/10/2021 |
8-K
| Investor presentation, Quarterly results |
| 11/04/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/26/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/19/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/03/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/12/2021 |
8-K
| Quarterly results |
|
|
|